Low Float (Nasdaq: CTOR) Moves Toward Key Commercial Milestone (High Anticipation Ahead)

A promising player in oncology is approaching a major inflection point.

*Sponsored Low Float (Nasdaq: CTOR) Moves Toward Key Commercial Milestone (High Anticipation Ahead) *Click Here To Get Our Alerts Faster Via SMS* December 1st Dear Reader, A promising player in oncology is approaching a major inflection point. After years of focused research and collaboration, the team is now preparing for a key commercial launch—a milestone set to redefine its presence in cancer care. With an innovative therapy aimed at improving patient outcomes and addressing critical treatment gaps, this company is steadily transitioning from clinical success to market execution. The next phase promises increased visibility, stronger operational momentum, and meaningful impact in an area of high unmet need. It’s an exciting moment to look more closely at what’s on the horizon. And with a low float meaning volatility potential could be significantly heightened on a daily basis, an analyst target pointing to triple-digit potential upside, and a commercial launch expected this quarter, this under-the-radar Nasdaq idea tops my watchlist: Citius Oncology, Inc. (Nasdaq: CTOR) Citius Oncology, Inc. is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400Mn, is growing, and is underserved by existing therapies. (1) And based on several potential catalysts, (Nasdaq: CTOR) has catapulted to the top of our watchlist. Check them out: #1. Could A Very Low Float Create An Environment For Heightened Volatility Potential? #2. A Key Collab With Verix Aims To Support LYMPHIR's Anticipated Q4 Commercial Launch. #3. A New Strategic Milestone Notched As CTOR Enters Into A Crucial Distro Services Agreement. #4. Commercialization Efforts Begin To Really Ramp Up As CTOR Signs Exclusive Agreement. #5. A Maxim Group Analyst Tags CTOR With A $6 Target. But more on those in a second... About Citius Oncology, Inc. Biopharmaceutical company focused on developing and commercializing innovative targeted  1.) Lead product, LYMPHIR, FDA approved August 2024 Orphan Indication: treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy 12-year BLA exclusivity First new systemic CTCL therapy since 2018  2.) Commercialization planned for Q4 2025 3.) Estimated $400Mn+ addressable U.S. market with growth opp's(1) 4.) Publicly traded on NASDAQ since August 2024 (Ticker: CTOR) Citius Is Preparing To Launch Lymphir In Q4 2025 Commercial launch readiness nearing completion through disciplined financial strategy What Is Cutaneous T-Cell Lymphoma (CTCL)? Considered to be incurable, CTCL is a Subgroup of Non-Hodgkin Lymphomas (NHL) that can be Indolent or Aggressive and is Driven by Malignant T Cells Patients with persistent or recurrent CTCL require systemic therapy. 1. Dummer R, et al. Nat Rev Dis Primers. 2021;7(1):61. 2. Rangoonwala, HI and Cascella M. 2022, StatPearls Publishing: Treasure Island, FL. 3. Cleveland Clinic. Cutaneous T-Cell Lymphoma. 2023. Available from: https0://my.clevelandclinic.org/health/diseases/17940-cutaneous-t-cell-lymphoma 4. Hristov AC, et al. Am J Hematol. 2019;94(9):1027-1041 Compelling Clinical Data LYMPHIR addresses CTCL’s heavy Quality of Life burden 1. Objective Response is Complete Response and Partial Response according to the ISCL/EORTC Global Response Score. 2. In the Primary Efficacy Analysis set, 84.4% (54/64) of skin evaluable subjects had a decrease in skin tumor burden, with 48.4% subjects with ≥50% reduction in skin tumor burden. Complete clearing of skin disease (skin CR) was observed in 12.5% (8/64)subjects. 3. The duration of response (DOR) was at least 6 months for 52% of responders and at least 12 months for 20% of responders (25/69 patients). Opp's For Growth Beyond Cutaneous T-cell Lymphoma (CTCL) University of Pittsburgh: an investigator-initiated trial is underway to evaluate LYMPHIR for potential use as an immuno-oncology therapy in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) Encouraging preliminary results of interim analysis: 15 evaluable patients showed 27% ORR; 33% Clinical Benefit Rate; median Progression Free Survival of 57 weeks (for patients that achieved a clinical benefit) The data supports further evaluation of this combination across a broader range of solid tumor types. Phase 1 Preliminary study data (n=25) anticipated Q4 2025/Q1 2026. University of Minnesota: LYMPHIR in combination with CAR T therapies (NCT04855253) Phase 1 study to evaluate the potential benefit of LYMPHIR given prior to CAR T therapy in patients with high risk relapsed/refractory B-cell lymphomas. Preliminary study results anticipated Q1 2026. Logical label expansion potential in PTCL where there is a high unmet need and no curative therapies. 1. KEYTRUDA is a registered trademark of Merck & Co., Inc. KYMRIAH is a registered trademark of Novartis Pharmaceuticals Corporation. Grab Sources And More Here: CTOR Presentation. ----- And as I mentioned previously, (Nasdaq: CTOR) has several potential catalysts helping catapult it to the top of our watchlist. Take a look: #1. CTOR Potential Catalyst - Could A Very Low Float Create An Environment For Heightened Volatility Potential? According to the Yahoo Finance website, CTOR has a very low float. In fact, the website reports this profile to have approximately 3.44Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could even more positive company news towards the end of 2025 provide a breakout spark when paired with this volatility potential? ----- #2. CTOR Potential Catalyst - A Key Collab With Verix Aims To Support LYMPHIR's Anticipated Q4 Commercial Launch. Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch CRANFORD, N.J., Nov. 21, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), ..., a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced a deeper collaboration with Verix, a leader in AI-powered commercial optimization technology for the life sciences sector. Citius Oncology's commercial team intends to further leverage Verix's innovative Tovana platform to support the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. Verix's Tovana platform integrates advanced analytics, real-world claims data, and machine learning to help inform Citius Oncology's commercial strategy and enable real-time field execution. The platform refines targeting over time and supports data-driven decisions, allowing the Citius Oncology commercial team to embed predictive intelligence into sales and marketing plans, and to prioritize engagement with high-impact healthcare providers (HCPs). Using company-defined criteria, the system identifies patterns in treatment and diagnosis, enabling Citius Oncology's commercial team to promptly engage prescribers whose patients may benefit from LYMPHIR. "We are committed to leveraging leading-edge technologies to maximize the commercial impact of LYMPHIR and look forward to using this innovative AI platform to amplify the precision and impact of our experienced commercial and marketing teams," stated Leonard Mazur, Chairman and CEO of Citius Oncology ... "Through our collaboration with Verix, we are able to enhance our salesforce's experience with the ability to identify key treatment patterns, personalize provider engagement, and allocate commercial resources efficiently. With LYMPHIR poised to become a meaningful new option for patients with relapsed or refractory CTCL, it's critical that our commercial organization has precision tools that accelerate physician engagement and product uptake. This data-driven approach positions us to execute a focused and impactful launch while maintaining a lean infrastructure," added Mazur. ... Read the full article here. ----- #3. CTOR Potential Catalyst - A New Strategic Milestone Notched As CTOR Enters Into A Crucial Distro Services Agreement. Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR CRANFORD, N.J., Oct. 20, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), ..., today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE: MCK), one of the largest pharmaceutical distributors and healthcare services companies in North America. Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunotherapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The agreement with McKesson completes Citius Oncology's core U.S. distribution network for LYMPHIR, which now includes all three of the largest pharmaceutical distributors in the country. This strategic milestone ensures broad and reliable access to the therapy in preparation for its planned commercial launch in the fourth quarter of 2025. "This agreement marks the final major component of our U.S. distribution strategy and reflects our deep commitment to ensuring that physicians and patients have timely access to LYMPHIR," said Leonard Mazur, Chairman and CEO of Citius Oncology ... "With a complete top-tier distribution network in place, we believe we are well-positioned to deliver on our promise to the CTCL community and execute a successful launch." ... Read the full article here. ----- #4. CTOR Potential Catalyst - Commercialization Efforts Begin To Really Ramp Up As CTOR Signs Exclusive Agreement. Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy CRANFORD, N.J., Oct. 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), ..., today announced it has finalized an exclusive agreement with EVERSANA®, a leading provider of global commercialization services, to support the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl), Citius Oncology's FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy. Under the Master Service Agreement, EVERSANA will serve as Citius Oncology's exclusive commercialization partner, providing an integrated suite of pre- and post-launch operations services. These services include medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management. As launch preparations advance, additional commercialization services are expected to be integrated. This agreement marks an expansion of EVERSANA's vital role in advancing Citius Oncology's pre-commercial strategy, building on the foundational work already completed in preparation for the U.S. launch of LYMPHIR. "Finalizing our exclusive agreement with EVERSANA is a transformative milestone as we prepare and plan to bring LYMPHIR to market in Q4 2025," said Leonard Mazur, Chairman and CEO of Citius Oncology ... "As a lean and strategically focused organization, this agreement allows us to significantly extend our commercial capabilities by leveraging EVERSANA's best-in-class infrastructure and deep expertise in oncology commercialization. EVERSANA's demonstrated ability to execute across the product lifecycle enhances our ability to scale efficiently, ensure timely market access for LYMPHIR, and support a high-quality launch aligned with in-vest-or expectations. We believe this collaboration strengthens our operational readiness, de-risks execution, and enhances our capacity to generate long-term value for shareholders." ... Read the full article here. ----- #5. CTOR Potential Catalyst - A Maxim Group Analyst Tags CTOR With A $6 Target. The Maxim Group has built one of the premier proprietary research platforms on Wall Street, with an emphasis on small-cap, micro-cap, and emerging growth companies. Michael Okunewitch, an analyst at Maxim Group covering the biotechnology sector, has suggested a $6.00 target for Citius Oncology as of 11/30/25 according to published info on the company’s website. With this $6.00 target, there could be upside potential of over 300% for CTOR from its closing valuation Friday. ----- (Nasdaq: CTOR) Recap - These 5 Potential Catalysts Could Draw Serious Buzz #1. Could A Very Low Float Create An Environment For Heightened Volatility Potential? #2. A Key Collab With Verix Aims To Support LYMPHIR's Anticipated Q4 Commercial Launch. #3. A New Strategic Milestone Notched As CTOR Enters Into A Crucial Distro Services Agreement. #4. Commercialization Efforts Begin To Really Ramp Up As CTOR Signs Exclusive Agreement. #5. A Maxim Group Analyst Tags CTOR With A $6 Target. ----- We're officially kicking-off coverage on Citius Oncology, Inc. (Nasdaq: CTOR). Be on the lookout for updates coming your way shortly. Talk soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer Sources: 1.) Internal CTOR estimates based on IQVIA market research (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 11/30/2025 and ending on 12/01/2025 to publicly disseminate information about (CTOR:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (CTOR:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/ctor-icnzj/#details

Fierce Investor | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice